Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Pavlik, Lauren; Regev, Arie; Ardayfio, Paul; Chalasani, Naga

doi:10.1007/s40264-018-00790-2

Cited by 24 publications

(23 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fatty liver can be caused by various factors, including medications, intestinal surgery, and pregnancy. [39][40][41][42] Therefore, it is also important to add specific etiological information regarding associated metabolic dysfunctions to the definition of fatty liver to clearly indicate the pathogenesis of the disease and to share the pathological information with the multidisciplinary team.…”

Section: Rationalementioning

confidence: 99%

MAFLD: Renovation of clinical practice and disease awareness of fatty liver

Kawaguchi

Tsutsumi

Nakano

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction‐associated fatty liver disease (MAFLD). MAFLD is not just a simple renaming of non‐alcoholic fatty liver disease (NAFLD). The unique feature of MAFLD is the inclusion of metabolic dysfunctions, which are high‐risk factors for events. In addition, MAFLD is independent of alcohol intake and the co‐existing causes of liver disease. This new concept of MAFLD may have a widespread impact on patients, medical doctors, medical staff, and various stakeholders regarding fatty liver. Thus, MAFLD may renovate clinical practice and disease awareness of fatty liver. In this review, we introduce the definition of and rationale for MAFLD. We further describe representative cases showing how the diagnostic processes differ between MAFLD and NAFLD. We also summarize recent studies comparing MAFLD with NAFLD and discuss the impact of MAFLD on clinical trials, Japanese populations, and disease awareness.

show abstract

Section: Rationalementioning

confidence: 99%

MAFLD: Renovation of clinical practice and disease awareness of fatty liver

Kawaguchi

Tsutsumi

Nakano

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Currently the only way to make the diagnosis of DIS is by the means of imaging studies or, less frequently, histology; whereas, DISH can be identified only if suspected patients undergo liver biopsy. What is more, an exhaustive clinical evaluation and comprehensive causality assessment to rule out other possible causes and determine the association with the suspected drug are required [ 7 ]. Even though they are distinct disorders, the slow progressive forms of DIS and DISH are often confused with or misdiagnosed as non-alcoholic fatty liver disease (NAFLD)—which has been recently renamed metabolic associated fatty liver disease (MALFD) [ 8 ]- or non-alcoholic steatohepatitis (NASH), which are much more common and, by definition, not caused by drugs.…”

Section: Introductionmentioning

confidence: 99%

New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants

et al. 2021

View full text Add to dashboard Cite

Drug-induced lipid accumulation in the liver may induce two clinically relevant conditions, drug-induced steatosis (DIS) and drug-induced steatohepatitis (DISH). The list of drugs that may cause DIS or DISH is long and heterogeneous and includes therapeutically relevant molecules that cannot be easily replaced by less hepatotoxic medicines, therefore making specific strategies necessary for DIS/DISH prevention or treatment. For years, the only available tools to achieve these goals have been antioxidant drugs and free radical scavengers, which counteract drug-induced mitochondrial dysfunction but, unfortunately, have only limited efficacy. In the present review we illustrate how in vitro preclinical research unraveled new key players in the pathogenesis of specific forms of DISH, and how, in a few cases, proof of

show abstract

“…24 For DIS/DISH diagnosis, liver biopsy is the standard means for confirmation of hepatic cell injury and liver inflammation. 52 Risk factors for occurrence of DIFLD Some drugs cause progression of MAFLD to MASH or cirrhosis, and may also worsen the prognosis in patients with fatty liver. 17 This conversion to MASH appears to involve genetic and environmental factors.…”

Section: Histology Of Difldmentioning

confidence: 99%

“… 50 , 51 Depending on the particular pathogenic mechanism of each lipotoxic drug, DIS/DISH can present as micro- or macrovesicular steatosis/steatohepatitis, but most cases start acutely with microvesicular injury. 52 The latency of DIFLD before clinical manifestations may vary. 24 For DIS/DISH diagnosis, liver biopsy is the standard means for confirmation of hepatic cell injury and liver inflammation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Drug-induced Fatty Liver Disease: Pathogenesis and Treatment

Kolarić

Ninčević

Kuna

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.

show abstract

Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Cited by 24 publications

References 52 publications

MAFLD: Renovation of clinical practice and disease awareness of fatty liver

MAFLD: Renovation of clinical practice and disease awareness of fatty liver

New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants

Drug-induced Fatty Liver Disease: Pathogenesis and Treatment

Contact Info

Product

Resources

About